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The Journal of Thoracic and CaA 56-year-old woman was hospitalized for hematuria
during December 2012. During examination she com-
plained of dyspnea at exertion. A new systolic murmur
was heard at auscultation.
Her past medical history mainly included rheumatic
heart disease. She underwent mitral valve repair in 1978.
A double mitroaortic valve replacement with Perimount
bioprostheses (Edwards Lifesciences, Irvine, Calif) was
performed first in 1988 and then in 1997. Recurrence of se-
vere mitral valve regurgitation (MR) occurred during Juneiew of the Sapien XT prosthesis (Edwards Lifesciences, Irvine, Calif)
n was excellent. Bottom, Intraoperative TEE view of the failed mitral
osthesis was responsible for the uncovering of the leaflets (*) from the failed
e Sapien XT prosthesis (**). Bottom right, Color Doppler view showing the
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FIGURE 2. Computed tomography scans showing the backward displacement of the Sapien XT prosthesis (Edwards Lifesciences, Irvine, Calif) over time.
Top left, Five days after valve-in-valve implantation. Top right, 18 months after valve-in-valve implantation. Bottom, Macroscopic findings during surgery
for late failure of mitral valve-in-valve implantation.Bottom left, Surgical view confirming the backward displacement of the Sapien XT prosthesis deployed
within the failed mitral Perimount prosthesis (Edwards Lifesciences). Bottom right, Ex vivo view showing the mechanism of the transprosthetic radially
oriented jet of mitral regurgitation.
Case Reports2011. This was related to prolapse of 1 leaflet secondary to
structural valve deterioration.
Despite an intermediate risk (logistic Euroscore, 11%)
the patient was considered at high risk for surgery
because of severe concomitant pulmonary hypertension
(systolic pressure, 87 mm Hg) and the multiple previous
sternotomies. The patient therefore underwent transapical
mitral valve-in-valve (ViV) implantation during June
2011. A 29-mm Sapien XT prosthesis (Edwards Life-
sciences) was uneventfully implanted under fluoroscopy
within the 29-mm mitral Perimount prosthesis. The
prosthesis overlapped the sewing ring of the failed
bioprosthesis. Intraoperative transesophageal echocardio-
graphy confirmed excellent mitral prosthesis function
(Figure 1). On postoperative computed tomography scan,
the height of the atrial part of the Sapien prosthesis varied
from 8 to 10 mm (Figure 2). Until the recent hospitalization,
the patient had been asymptomatic with excellent prosthesis
function on repeated transthoracic echocardiogram.
Recurrence of severe MR 17 months after the ViV
implant was attributed to backward slippage of the
previously implanted Sapien XT prosthesis. On computed
tomography scan, the height of the atrial part of the Sapien
XT was almost 13 mm (Figure 2). Secondary to thise60 The Journal of Thoracic and Cardiovascular Surgdislodgment, the leaflets of the mitral Perimount prosthesis
became uncovered and mobile (Figure 1). One leaflet from
the Sapien XT prosthesis had an intermittent restrictive
pattern of motion. Two jets of MR were visible. One,
totally intraprosthetic, was related to the restrictive
motion of 1 leaflet from the Sapien XT prosthesis
(Figure 1). The second jet originated from the lumen of
the Sapien XT prosthesis and radially crossed the stent of
the percutaneous valve. This was due to the fact that
following prosthesis dislodgment the distal extremity of
the fabric skirt of the Sapien XT prosthesis was upstream
of the sewing ring of the mitral Perimount prosthesis
(Figure 2).
As a result of the severity of MR, a double mitral and
aortic valve replacement was performed with 2 mechanical
bileaflet prostheses. The intraoperative findings revealed
the backward displacement of the prosthesis and confirmed
the mechanism of the lateral jet of MR (Figure 2).
The explanted Sapien prosthesis was macroscopically
normal. The postoperative course of the patient was
uneventful.
Only a few dozen mitral ViV implants have been
reported.1,2 Despite this, at least 4 cases (including ours)
of delayed prosthesis migration have been described.1,3ery c May 2014
Case ReportsThus, this complication is not infrequent and might
therefore be a real concern in the future.
The reasons for occurrence of such a complication are
multifactorial. First, the conjunction of a high transvalvular
(systolic) gradient applied to large size prosthesis leads to
an increased retrograde migration force. Second, too
much atrial protrusion of the prosthesis may favor its
retrograde displacement. This could have been the case in
our patient. Third, underexpansion of the prosthesis might
play a major role. This can result from inadequate sizing
(which seemed not to be the case with our patient) rather
than a technical problem (eg, balloon rupture or insufficient
filling volume of the balloon). Fourth, failed bioprosthesis
with no or mild leaflet calcification may also be at risk.
This was the case in our patient and in another reported
on by Bapat and colleagues.3 Finally, the stent shape of
the deployed prosthesis may have a major role. Some
fluoroscopic aspects (eg, rectangular or trapezoidal with
the larger base facing the atrial cavity) are prone to
secondary migration. The rectangular fluoroscopic aspect
was present in the cases reported by Bapat and colleagues3
and in our patient.
In the literature, prosthesis migration occurred 6 days to
3 months after the procedure. Clinical presentation was
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showing excessive atrial protrusion of the valved stent.
Severe mitral dysfunction secondary to retrograde
prosthesis migration after mitral ViV has been successfully
treated by either surgical mitral valve replacement or redo
mitral ViV.1,3
Our report is important because it shows that prosthesis
dislodgment may occur late (>1 year) after ViV. Close
follow-up is mandatory, especially in at-risk patients.
Furthermore, due to a probable high risk of delayed
migration, criteria for proper prosthesis implantation should
be accurately defined in this setting. Our observation with
previous reports may also incite valve manufacturers to
improve the design of the currently available percutaneous
prostheses used for ViV implantation.References
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2014;83:E150-4.Percutaneous closure of paravalvular leak in children after left
ventricular outflow enlargement by the Konno procedure with aortic
valve mechanical prosthesisLilia Oreto, MD,a Fiore Salvatore Iorio, MD,a Giacomo Pongiglione, MD, FACC,b and
Paolo Guccione, MD,a Taormina and Rome, ItalyA clinically significant paravalvular leak (PVL) is a
complication of valve replacement with estimated inci-
dence up to 9% in adults.1 However, the incidence of
PVL in children is not reported and its occurrence aftersurgical enlargement of the left ventricular outflow tract
(LVOT) and the aortic annulus is rarely described. Although
a surgical approach has been considered the preferred treat-
ment, it is burdened by high incidence of recurrent leakages
and significant morbidity and mortality.1,2 During the past
decade a percutaneous approach to PVL has been
increasingly employed in an effort to overcome surgery-
related limitations, to the point that successful results are
reported in up to 90% of treated patients.3,4 However,
transcatheter treatment of PVL in children has been
reported after mitral valve replacement but never after
aortic valve replacement.5 We report the experience of
transcatheter closure of aortic PVL in 2 children after
they underwent the Konno procedure and prosthetic aortic
valve implantation.rdiovascular Surgery c Volume 147, Number 5 e61
